Clinical Study On Treatment Of Coronary Heart Disease With Unstable Angina Pectoris With Qi Deficiency And Phlegm And Blood Stasis Syndrome By

Objective The curative effect and safety of the Huxinkang tablet on the unstable angina pectoris (UAP) with the syndrome of Qi deficiency and phlegm and blood stasis (QDPBS) is observed, and its effect on the homocysteine (Hcy), high sensitivity C-reactive protein (hs-CRP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) is discussed.Methods On the basis of random number table method,60inpatients of UAP with the syndrome of QDPBS in the Affiliated Hospital of the Hunan Academy of Chinese Medicine were selected and randomly divided into the treatment group (30cases) and control group (30cases). All patients were administered with the same basic western medicine treatment. The patients in the treatment group were treated with the Huxinkang tablet plus the basic western medicine treatment, while patients in the control group are treated with the Tongxinluo capsules plus the basic western medicine treatment. The treatment course was four weeks. The clinical effect and curative effect of the angina pectoris (AP), electrocardiograph (ECG) and Chinese medicine syndrome (CMS) are observed after the treatment, as well as the change of indices of the blood fat, Hcy, hs-CRP and NT-proBNP before and after the treatment.Results (1) The total effective rate of the clinical curative effect was90.0%in treatment group but76.7%in the control group. There was a significant difference between the two groups (P<0.05).(2) The total effective rate of the ECG curative effect was80.0%in treatment group but63.3%in the control group. There was a significant difference between the two groups (P<0.05).(3) The total effective rate of the AP curative effect was86.7%in treatment group but66.7%in the control group. There was a significant difference between the two groups (P<0.05).(4) The total effective rate of the glonoine reduction was90.0%in treatment group but76.7%in the control group. There was a significant difference between the two groups (P<0.05).(5) The total effective rate of the CMS curative effect was90.0%in treatment group but73.3%in the control group. There was a significant difference between the two groups (P<0.05).(6) The blood fat are improved in both two groups, and there were significant differences before and after the treatment in both two groups (P<0.05). Besides, these indices of the treatment group are superior to those of the control group, and there was a significant difference between the two groups (P<0.05).(7) The Hcy, hs-CRP and NT-proBNP are reduced in both two groups, and there were significant differences before and after the treatment in both two group (P<0.05). Moreover, these indices of the treatment group are superior to those of the control group, and there was a significant difference between the two groups (P<0.05).(8) There was no obvious change of the dectetion of the blood, electrolyte, and liver and kidney function in both two groups, as well as no serious adverse reaction, and there was no statistical signification in and between two groups (P>0.05), thus both two drugs are provided with good safety.Conclusion There was an exact and safe curative effect of the Huxinkang tablet in the treatment of the UAP patients with the syndrome of QDPBS, which can improve the lipid metabolism function and suppress the levels of the Hcy, hs-CRP and NT-proBNP, thus it is worthy of the clinical promotion and further research.